[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
OBJECTIVE
To analyze a Duchenne muscular dystrophy(DMD) patient's muscular regeneration, dystrophin expression and locomotive variation before and after he underwent umbilical cord blood stem cell transplantation in order to assess the therapeutic effect.


METHODS
A 12-year-old DMD boy who could not walk for 3 years was confirmed by gene analysis and dystrophin protein immune test on his muscle. He had no other chronic disease. By HLA matching, a piece of umbilical cord blood stem cell with 6 HLA sites matching to the boy was found in Guangdong Umbilical Cord Blood Bank. The number of the nucleated cells of the umbilical cord blood stem cell was 24.08x 10(8). After pretreatment for the DMD boy with busulfan, cyclophosphamide and rabbit anti-human thymocyte globulin, the allergenic cord blood stem cells were transplanted into him by intravenous injection. Cyclosporin A, methylprednisolone, MMF, prostaglandin E1 and ganciclovir were given after the transplantation. At the same time, Gran, the granulocytic cell stimulating factor, and gamma globulin were administered. The biochemistry profile including serum creatine kinase (CK), the reconstruction of blood making, the deletion exon of DMD gene, the regenerating muscles, the dystrophin protein expression, and the locomotive function of the DMD boy were tested regularly.


RESULTS
(1) The white blood cells (WBC) of peripheral blood decreased gradually to zero after pretreatment. In a period of 15 days after transplantation, the neutrophil increased to 0.5x 10(9)/L; at 25 days, WBC increased to normal level. Blood platelet was more than 20x 10(9)/L at 22 days. The hemoglobin rose to 85-100 g/L. At 140 days, sternal puncture revealed the rapid growth of neutrophil, blood platelet and hemoglobin. (2)At 140 days, the blood type of the DMD boy transformed from type O to type AB (the donor's blood type being AB). There was no grafe versus host reaction. (3) At 18, 30, 43, 55, 74 and 233 days after transplantation, the PCR-short tandem repeat test of the boy's peripheral blood DNA showed that his genotype was completely the same as the donor's. The results of PCR-short tandem repeat tests of the bone marrow cells DNA by sternal puncture at 140, 183 and 235 days were the same as those of the blood DNA. (4) At 60 days, DMD gene analysis by PCR showed that the defected DMD gene (exon 19 deletion) had been corrected by the umbilical cord stem cells transplantation. (5) At 75 days, the biopsy of calf muscle showed there were myoblast cells and muscular tubes growing. The dystrophin expressions were weak, but a few of them were strong. DNA analysis showed that the donor's gene DNA accounted for 1%-13%. At 126 days, obviously increased dystrophin positive muscular fibers of the boy were found. The donor's fibers rose to 2.5%-25%. (6) The serum CK of the boy declined from 5735 U/L to 274 U/L. (7) At 100 days, physical examination revealed improvement in his arms and legs.


CONCLUSIONS
The therapy of Duchenne muscular dystrophy with allogeneic umbilical cord blood hematopoietic stem cell transplantation may reset up the blood-making function, decrease the serum CK level, restore the dystrophin in muscles, and improve the locomotive function of the DMD boy. These data suggest that the allogeneic umbilical cord blood hematopoietic stem cell transplantation may benefit the DMD boys.
Zhang
Cheng
C
Department of Neurology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080 PR China.
Feng
Hui-yu
HY
Huang
Shao-liang
SL
Fang
Jian-pei
JP
Xiao
Lu-lu
LL
Yao
Xiao-li
XL
Chen
Chun
C
Ye
Xin
X
Zeng
Yin
Y
Lu
Xi-lin
XL
Wen
Jian-ming
JM
Zhang
Wei-xi
WX
Li
Zhong
Z
Feng
Shan-wei
SW
Xu
Hong-gui
HG
Huang
Ke
K
Zhou
Dun-hua
DH
Chen
Wei
W
Xie
You-mei
YM
Xi
Jing
J
Zhang
Meng
M
Li
Yang
Y
Liu
Ying
Y
D000527:Alprostadil / Q000627:therapeutic use; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D016572:Cyclosporine / Q000627:therapeutic use; D016189:Dystrophin / Q000235:genetics; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000628:therapy*; D016133:Polymerase Chain Reaction; D016896:Treatment Outcome
D016189:Dystrophin; D016572:Cyclosporine; D000527:Alprostadil; D002066:Busulfan; D015774:Ganciclovir; D008775:Methylprednisolone